H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $13.00 price target on Karyopharm Therapeutics (NASDAQ: KPTI).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments